Pfizer, Inc. : Close to new upside potential
Entry price | Target | Stop-loss | Potential |
---|
US$37.39 |
US$44.7 |
US$33.9 |
+19.55% |
---|
Below the resistance zone that is currently being tested, the potential for new gains appears limited for shares in Pfizer Inc.. The stock's technical chart pattern suggests however that the level will be broken.
Summary● The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
● In a short-term perspective, the company has interesting fundamentals.
Strengths● Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
● Considering the small differences between the analysts' various estimates, the group's business visibility is good.
● Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
Weaknesses● The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
● The company is in debt and has limited leeway for investment
● Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
● The company's enterprise value to sales, at 5.06 times its current sales, is high.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.